Centric Wealth Management Sells 90,514 Shares of Pfizer Inc. $PFE

Centric Wealth Management lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 74.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 30,866 shares of the biopharmaceutical company’s stock after selling 90,514 shares during the quarter. Centric Wealth Management’s holdings in Pfizer were worth $761,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Pfizer during the 2nd quarter valued at about $2,270,157,000. Vanguard Group Inc. boosted its stake in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after buying an additional 10,198,330 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Pfizer by 43.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after buying an additional 5,662,309 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Pfizer by 75.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock worth $221,398,000 after acquiring an additional 3,722,531 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Pfizer by 84.9% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock worth $183,302,000 after acquiring an additional 3,472,240 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on PFE. Bank of America cut their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Citigroup assumed coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective for the company. Scotiabank assumed coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.06.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla is doubling down on oncology with a roughly $23 billion post?COVID investment plan, positioning Pfizer as a major growth bet on cancer therapies — a strategic pivot investors see as a multi?year revenue driver. ‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post?COVID bet on oncology
• Positive Sentiment: Pfizer struck a non?exclusive licensing agreement to access Novavax’s Matrix?M adjuvant technology (reported value ~$530M), which could boost future vaccine efficacy and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix?M Adjuvant Technology
• Positive Sentiment: A bullish technical/forecast note projects upside toward ~$36.16, which can attract momentum and speculative buying. PFIZER Stock Holds Near $25.86 as Forecast Targets $36.16 Upside
• Neutral Sentiment: Pfizer is due to report Q4 and full?year 2025 results before the market opens Feb. 3; consensus Q4 estimates cited are ~$16.9B sales and $0.57 EPS — the upcoming print is the near?term catalyst. Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
• Neutral Sentiment: Zacks and other outlets report heightened retail/investor attention on PFE and provide deeper metric estimates ahead of earnings — increased search/coverage can amplify moves on the print. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Background pieces (portfolio company lists, Wall Street metric breakdowns) add context but are unlikely to move the stock materially on their own. 7 Companies Owned by Pfizer
• Negative Sentiment: Critical commentary warns of valuation and execution risks (Seeking Alpha: “Buyer Beware”) and highlights that risks may outweigh near?term rewards, which can pressure sentiment. Pfizer: Buyer Beware, The Risk Outweighs The Reward
• Negative Sentiment: Media coverage of past management tactics (CEO comments on extreme COVID-era measures) and notes that PFE has recently underperformed peers may feed governance/PR concerns and short?term selling. Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19 Pfizer Inc. stock underperforms Wednesday when compared to competitors

Pfizer Stock Performance

Pfizer stock opened at $26.43 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The firm has a market capitalization of $150.24 billion, a P/E ratio of 15.36 and a beta of 0.47. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The company’s 50-day moving average is $25.52 and its 200 day moving average is $25.03.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.